PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.02
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$188.14

08 Apr
2025

11.260

OPEN

$182.02

6.37%

HIGH

$189.00

408,885

LOW

$182.00

TARGET
$252.48 34.2% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 79.3 110.2 xxx
DPS (cps) xxx 40.0 53.9 xxx
EPS Growth xxx 36.5% 39.1% xxx
DPS Growth xxx 33.3% 34.8% xxx
PE Ratio xxx N/A 170.8 xxx
Dividend Yield xxx N/A 0.3% xxx
Div Pay Ratio(%) xxx 50.5% 48.9% xxx

Dividend yield today if purchased 3 years ago: 0.83%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.21

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 22c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx79.3
DPS All xxxxxxxxxxxxxxx40.0
Sales/Revenue xxxxxxxxxxxxxxx161.5 M
Book Value Per Share xxxxxxxxxxxxxxx179.8
Net Operating Cash Flow xxxxxxxxxxxxxxx86.8 M
Net Profit Margin xxxxxxxxxxxxxxx51.27 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx50.72 %
Return on Invested Capital xxxxxxxxxxxxxxx50.30 %
Return on Assets xxxxxxxxxxxxxxx36.03 %
Return on Equity xxxxxxxxxxxxxxx50.72 %
Return on Total Capital xxxxxxxxxxxxxxx67.94 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx49.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx155 M
Price To Book Value xxxxxxxxxxxxxxx79.69

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx6.7 M
Capex % of Sales xxxxxxxxxxxxxxx4.14 %
Cost of Goods Sold xxxxxxxxxxxxxxx39 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx7 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.4

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

26/03/2025

1

Upgrade to Add from Hold

$250.00

32.88%

Following a deeper analysis of Pro Medicus' $330m 10-year deal with Trinity Health, Morgans understand revenue will be lower over the first 18 months and pick up across the final 8 years.

This is due to phased implementation given the complexity of replacement in sites under existing contracts. This has resulted in near-term downgrades in the broker's forecast and upgrades later, and hence no change in the valuation.

Target price retained at $250. Rating upgraded to Add from Hold following recent share price weakness.

FORECAST
Morgans forecasts a full year FY25 dividend of 56.00 cents and EPS of 113.00 cents.
Morgans forecasts a full year FY26 dividend of 89.00 cents and EPS of 178.00 cents.

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

17/02/2025

3

Downgrade to Market Weight from Overweight

$297.00

57.86%

Pro Medicus' 1H25 topline revenue of $97M missed Wilsons' estimate by -7% but the broker admits it was a case of its forecast being too high. Overall, directionally the result met the broker's expectations.

The broker lowered FY25 revenue estimates on account of the 1H miss while leaving 2H forecasts unchanged. FY26 forecast was lifted by 1.2% owing mainly to new contracts.

Target price rises to $297 from $275 but rating lowered to Market Weight from Overweight.

FORECAST
Wilsons forecasts a full year FY25 dividend of 53.70 cents and EPS of 107.70 cents.
Wilsons forecasts a full year FY26 dividend of 67.80 cents and EPS of 137.20 cents.

Goldman Sachs

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

PME STOCK CHART

FNArena News on PME

1
Rudi’s View: Share Market Scenarios & Dilemmas

10:05 AM - Rudi's View
2
March In Review: Gold Shines As Tech Suffers

Apr 03 2025 - Australia
3
Megaport’s Quest Of Data Centre Agnostic Growth

Apr 03 2025 - Small Caps
4
Rudi’s View: Time For Appreciating Quality

Apr 02 2025 - Rudi's View
5
Weekly Ratings, Targets, Forecast Changes – 28-03-25

Mar 31 2025 - Weekly Reports

Latest Medical Equipment & Devices News

1
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
2
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
3
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
4
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
5
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
6
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
7
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
8
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
9
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
10
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps